hormone receptor +

Questions discussed in this category

When would you use adjuvant abemaciclib in patients with clinically high-risk ER+, HER2-negative breast cancer, but pCR following neoadjuvant chemotherapy?

Patient is a post-menopausal woman with 4 lymph node mets that was strongly ER+/PR+, HER2-negative invasive ductal carcinoma with a high Ki-67 w...

1 Answer available

Would you still obtain Ki-67 prior to use of adjuvant abemaciclib in a patient who has otherwise met MonarchE treatment criteria, such as 1-3 positive LNs, grade 3 and/or tumor >5 cm?

Patient is pre-menopausal and has cT3cN1, grade 2, ER positive, Her 2 negative IDC. Metastatic disease to axillary LNs was biopsy-proven. Patient was ...

1 Answer available

Is there a clinically significant increased risk of venous thromboembolism with the use of fulvestrant for metastatic HR+ breast cancer?

In a patient with a history of VTE (now off anticoagulants), is it safe to administer fulvestrant?

1 Answer available

What is the preferred sequence of systemic therapy in a patient with endocrine resistant HR+ metastatic breast cancer?

The patient previously received endocrine therapy alone and in combination with CDK 4/6 inhibitor. She does not have any targetable mutations on NGS. ...

1 Answer available

Would you consider a CDK 4/6 inhibitor in combination with endocrine therapy for a patient with ER low (1-9%) metastatic breast cancer?

In which situations would you consider this a reasonable treatment option?

1 Answer available

How do you treat leptomeningeal disease in metastatic HR+ HER2- breast cancer?

The patient is treatment naïve and asymptomatic. She also has disease in the body (bone and liver metastases).

1 Answer available

Would you consider a treatment holiday in a patient with HR+ oligometastatic breast cancer who is in a prolonged remission?

The patient initially received definitive therapy with AC-T and RT to the breast as well as RT to a solitary bone lesion. She has been on AI for the l...

3 Answers available

How does age factor into your planning whether to give a high risk pre-menopausal patient with breast cancer ovarian function suppression?

Do you have a specific age cutoff?

2 Answers available

In a patient with HR+ breast cancer who is not able to tolerate adjuvant AI or standard dose tamoxifen due to side effects, would you consider a lower dose of tamoxifen?

1 Answer available

What adjuvant chemotherapy would you recommend in a premenopausal patient with pT1cN1 HR+ breast cancer who previously received an anthracycline and cyclophosphamide 30 years prior?

The patient was diagnosed with Ewing’s Sarcoma at the age of 10 and completed 6 cycles of vincristine, ifosfamide, etoposide, adriamycin 75mg/m2...

2 Answers available